https://www.selleckchem.com/pr....oducts/apx-115-free-
Baseline characteristics and the safety profile were comparable between the groups. However, fatigue (22.8% versus 13.0%) and decreased appetite (8.8% versus 1.2%) were more frequent in elderly patients. Younger versus elderly patients equally benefited in terms of objective response rate (36% versus 48%), median progression-free survival (5.6 versus 5.5months; hazard ratio [HR]=1.03; p=0.81) and OS (10.6 versus 10.2months; HR=0.89; p=0.4). In addition, the median treatment duration (5 versus 4 cycles), relative dose intensity
Beğen
Yorum Yap
Paylaş
